Electroconvulsive Therapy for Treatment-Resistant Schizophrenia

Diarmid J. M. Sinclair; Sai Zhao; Fang Qi; Kazare Nyakyoma; Joey S. W. Kwong; Clive E. Adams


Schizophr Bull. 2019;45(4):730-732. 

In This Article

Authors' Conclusions

Moderate-quality evidence indicates that relative to standard care, ECT has a positive effect on medium-term clinical response for people with treatment-resistant schizophrenia. However, there is no clear and convincing advantage or disadvantage for adding ECT to standard care for other outcomes. The available evidence was too weak to indicate whether adding ECT to standard care is superior or inferior to adding sham-ECT or other antipsychotics to standard care. There was insufficient evidence to support or refute the use of ECT alone. Substantial good-quality evidence is needed before firm conclusions can be made. Full details are published in the Cochrane Review.[1]